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Abstract 1-Farnesylpyridinium (FPy), an analog of isoprenoid
farnesol, initially induced morphological changes similar to those
of typical apoptosis in human leukemia HL-60 cells but FPy-
treated cells were characterized by the absolute absence of final
apoptotic events such as fragmentation into apoptotic bodies.
FPy-induced cell death was considered to be apoptotic on the
basis of the induction of DNA fragmentation and the protection
against these events by the coaddition of a pan-caspase inhibitor.
The increase in the cytoplasmic cytochrome c level supported the
possibility that FPy-treated cells should have the ability to
complete the entire apoptotic process ending in cell fragmenta-
tion and apoptotic body formation. At concentrations too low to
induce apoptosis, FPy could suppress the induction of apoptotic
body formation in HL-60 cells by typical inducers of apoptosis
such as actinomycin D or anisomycin. FPy exhibited a
cytochalasin-like effect on spatial arrangement of actin filament
independent of its apoptosis-inducing activity. ß 2002 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Farnesyl pyrophosphate is an intermediate in the biosyn-
thetic reaction of cholesterol and non-sterol isoprenoids, in
which 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reduc-
tase produces mevalonate as a rate-limiting enzyme of the
reaction [1]. Farnesyl pyrophosphate and geranylgeranyl py-
rophosphate are also required for the post-translational mod-
i¢cation of diverse cell proteins such as nuclear lamins,
G proteins and small GTP-binding proteins of the Ras super-
family [2]. The overall inhibition of isoprenoid biosynthesis
can be attained by the addition of competitive inhibitors of
HMG-CoA reductase such as lovastatin and these inhibitors
have also been shown to induce apoptosis of various cell lines
including human lung adenocarcinoma A549 [3^5]. Exposure
of cells to farnesol (FOH) and geranylgeraniol results in apo-
ptosis in a number of neoplastically transformed cells [6^9].
FOH was found to inhibit isoprenoid metabolism by acceler-
ating degradation of HMG-CoA reductase rather than by
acting as a competitive inhibitor of farnesyl :protein transfer-
ase [10,11].
Apoptosis is characterized by a series of morphological
changes involving disappearance of cell surface microvilli,
cell shrinkage, chromatin condensation and nuclear collapse
[12,13]. Internucleosomal DNA fragmentation is another fea-
ture of apoptosis and is caused by a caspase-dependent acti-
vation of endonuclease [14]. At the ¢nal stage, apoptotic cells
are fragmented into membrane-bound small particles, the so-
called apoptotic bodies, possibly to enhance the phagocytic
ingestion of dead cells and to enhance elimination of their
macromolecular constituents [15^18]. The actin cytoskeleton
appears to play an essential role in apoptotic morphological
changes as deduced from the alteration of its spatial arrange-
ment, resulting from ¢lamentous actin disorganization and
reorganization [15,16,19]. In apoptosis of HL-60 cells under-
going apoptosis, apoptotic body formation was suppressed by
the coaddition of cytochalasin B, an agent which can inhibit
actin polymerization [15].
FOH has previously been structurally modi¢ed to give to-
cotrienol [20^22], menaquinone-3 [23], farnesylthiosalicylic
acid [24,25], farnesyl thioacetate [26] and farnesylamine [27^
29], and most of these hybrid molecules have been shown to
have greater in vitro tumor suppressive potency than FOH
itself against various cell lines. This means that the cytotox-
icity of FOH primarily depends on its isoprenoid hydrocarbon
structure and can be elevated or modi¢ed by varying the
structure of the attached group. We synthesized 1-farnesylpyr-
idinium (FPy) as a novel analog of FOH (Fig. 1). FPy-treated
HL-60 cells initially underwent morphological changes similar
to those of typical apoptosis, but showed the complete ab-
sence of fragmentation into small particles or apoptotic
body formation. We focussed our attention on the intracellu-
lar events involved in FPy-induced cell death accompanying
this unusual morphological pro¢le.
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2. Materials and methods
2.1. Cell culture
The HL-60 cells were maintained in RPMI 1640 medium (Sigma)
supplemented with 10% heat-inactivated fetal bovine serum (Sigma),
100 Wg/ml penicillin, and 100 Wg/ml streptomycin. The cells were
grown in a humidi¢ed incubator at 37‡C under a 5% CO2/95% air
atmosphere and used for assays during the exponential phase of
growth. Unless otherwise stated, con£uent cells were then seeded in
1 ml of fresh medium in 48-well plates at an initial density of 106 cells/
ml and incubated with or without chemical treatment for the indicated
times in each of the following experiments. Precultivation was nor-
mally done for 2 h in the fresh medium prior to the addition of each
chemical.
2.2. Microscopic observations of morphology, nuclear fragmentation
and actin micro¢lament
Cells were harvested by centrifugation, washed with phosphate-
bu¡ered saline (PBS) and ¢xed with 1% glutaraldehyde in 100 Wl of
PBS for 1 h at room temperature. Fixed cells were washed with PBS,
stained with 200 WM Hoechst 33258 in 20 Wl of PBS, and observed
and counted under phase-contrast £uorescence microscopes. Fixed
cells were stained with rhodamine^phalloidine for visualization of
actin micro¢laments [19].
2.3. Assay of DNA fragmentation
Cells were harvested by centrifugation and incubated in 400 Wl of
lysis bu¡er (10 mM Tris^HCl, pH 7.4; 10 mM EDTA; 0.5% SDS;
1 mg/ml proteinase K) at 37‡C overnight. After puri¢cation and
enrichment of the DNA in each lysate, the ¢nally obtained DNA
samples were subjected to electrophoresis in 1% agarose gels [16].
2.4. Assay of mitochondrial membrane potential
Con£uent cells were seeded in 1 ml of fresh medium at an initial
density of 106/ml, preincubated for 2 h and further incubated for 10
min after supplementation with 2 WM rhodamine 123. After incorpo-
ration of the £uorescent probe, cells were incubated for the indicated
times with or without FPy, harvested by centrifugation and then
suspended in 100 Wl of PBS after they were washed once with PBS.
The £uorescence intensity of each cell suspension was measured at an
excitation wavelength of 480 nm and an emission wavelength of 530
nm in a Cyto£or 2300 £uorescence spectrophotometer. The £uores-
cence intensity was used as an arbitrary unit representing the mito-
chondrial transmembrane potential.
2.5. Western blot analysis of cytochrome c (Cyt c)
Cells were seeded in 3 ml of fresh medium at an initial density of
106/ml and incubated for the indicated times with or without addition
of FPy. Cells were harvested by centrifugation and washed once with
lysis bu¡er (30 mM Tris^HCl, pH 7.4; 5 mM KH2PO4 ; 40 mM KCl;
0.5 mM EDTA; 3 mM MgCl2 ; 75 mM sucrose; 20 mM D-glucose).
Cells were suspended in 300 Wl of this bu¡er and lysed by the addition
of 5 mg of digitonin and incubation at 37‡C for 7 min. An aliquot
(equivalent to 20 Wg of protein) of the supernatant obtained after
centrifugation of each cell lysate was dissolved in SDS-sample bu¡er
(125 mM Tris^HCl, pH 6.8; 4% SDS; 10% mercaptoethanol; 20%
glycerol; 0.002% bromophenol blue) and boiled for 5 min. The sam-
ples were subjected to SDS^PAGE on a 15% polyacrylamide gel fol-
lowed by electrophoretic transfer of the proteins in the gel to a PVDF
membrane (Amersham) for 4 h at 200 mA. The membrane was in-
cubated with a primary antibody against Cyt c (1:1000 dilution) and
then with horseradish peroxidase-linked secondary antibody (1:1000
dilution) against mouse IgG. The band of Cyt c was visualized by
chemiluminescence using the ECL Western Blotting Detection kit
(Amersham).
2.6. Synthesis of FPy
To prepare FPy, a mixture of farnesyl chloride (144 mg, 0.6 mmol)
and dehydrated pyridine (2.5 ml) was heated at 80‡C for 1 h. After
cooling to room temperature, the resulting mixture was diluted with
two parts of dichloromethane and applied onto a silica gel column.
Elution with dichloromethane followed by 5% methanol in dichloro-
methane a¡orded FPy as a yellowish gummy liquid in 90% yield. Its
chemical structure (Fig. 1) was elucidated based on the FAB(+)-MS
m/z value of 284 (M) which was detected using a JEOL JMS-700T
mass spectrometer, and the NMR spectrum determined using a JEOL
JNM-LA400 NMR spectrometer in chloroform-d1 at 40‡C.
2.7. Other chemicals
FOH, farnesyl chloride, actinomycin D (Act D), anisomycin,
Hoechst 33258, rhodamine 123 and dihydrocytochalasin B (H2CB)
were obtained from Sigma. Rhodamine^phalloidine was from Molec-
ular Probes, Inc. 1-Laurylpyridinium (LPy) was a product of Wako
Pure Chemical Co. (Japan). Carbobenzoxy-valyl-alanyl-aspartyl-[O-
methyl]-£uoromethylketone (Z-VAD-fmk) and carbobenzoxy-L-as-
part-1-yl-[(2,6-Dichlorobenzoyl)oxy]methane (Z-Asp-CH2-DCB) were
purchased from the Peptide Institute (Japan). The anti-Cyt c antibody
was a product of Pharmingen.
3. Results and discussion
3.1. Evaluation of FPy-induced cell death
FOH-treated cells showed typical apoptotic morphological
changes such as cell shrinkage and nuclear fragmentation, and
were ultimately fragmented into apoptotic bodies, as shown in
Fig. 2C,CP. FPy-induced cell death exhibited morphological
changes similar to those in FOH-treated cells, but later exhib-
ited an unusual morphological event, namely, failure in frag-
mentation into small particles or apoptotic bodies even at 6 h
of incubation (Fig. 2B). The initially formed shrunken and
spherical cell shape was maintained with no additional mor-
phological changes for at least 12 h of incubation and, there-
after the whole cell structure was gradually lost without any
sign of apoptotic body formation. As is the case for the main
chain of the isoprenoid hydrocarbon of FPy, the linear chain
of LPy consists of 12 carbon atoms with no methyl side chains
(Fig. 1). LPy caused a di¡erent type of cytotoxicity, namely
one accompanied by drastic cell lysis or plasma membrane
collapse, re£ecting an ability to induce necrotic cell death or
a detergent-like property (Fig. 2D,DP).
In spite of the failure of cell fragmentation, nuclear frag-
mentation was clearly observed with FPy-treated cells (Fig.
2BP), suggesting the possibility that FPy may selectively a¡ect
nuclear membrane assembly or interfere with some mecha-
nism essential for maintenance of the nuclear structure.
3.2. FPy-induced intracellular events
As shown in Fig. 3, DNA ladders were observed in FPy-
treated cells in a time-dependent and dose-dependent manner,
along with the increase in the number of cells carrying frag-
mented nuclear particles. FPy-induced nuclear fragmentation
may thus be an apoptotic event provoked along with endo-
nuclease activation via a caspase family member. The caspase
cascade functions to achieve a number of apoptotic events
including actin depolymerization, poly(ADP-ribose) polymer-
ase inactivation and endonuclease activation [14,30]. We ex-
amined whether or not the caspase cascade was involved in
the progression of the unusual morphological changes in FPy-
treated cells by using pan-caspase inhibitors such as Z-VAD-
fmk and Z-Asp-CH2-DCB [31^33]. FPy-induced nuclear col-
lapse and DNA fragmentation were fully suppressed by the
coaddition of each of these inhibitors at 100 WM (data not
shown).
Several lines of evidence indicate that activation of caspase
cascade can be achieved through mitochondrial Cyt c release
[34,35]. Fig. 4 shows a clear time-dependent increase in the
cytoplasmic Cyt c level in FPy-treated cells in parallel with
time-dependent mitochondrial transmembrane depolarization.
These FPy-induced intracellular events imply that FPy-treated
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cells should have the ability to complete the entire apoptotic
process ending in cell fragmentation and apoptotic body for-
mation.
3.3. Protective e¡ect of FPy against apoptotic body formation
and actin organization
Cytochalasins are fungal metabolites that can prevent actin
polymerization or cause actin depolymerization, thereby dis-
rupting micro¢lament network interactions in vivo [36]. In
accordance with previous reports [15,19], H2CB did not pro-
voke any apoptotic event by itself but could e¡ectively prevent
the formation of apoptotic bodies without causing any pro-
tective e¡ect against other apoptotic events such as cell
shrinkage and nuclear collapse induced with Act D (Fig. 5).
H2CB exhibited exactly the same type of protective e¡ect
against apoptotic body formation induced by anisomycin,
an inhibitor of protein synthesis.
It was examined whether FPy can protect against apoptotic
body formation in medium containing either Act D or aniso-
mycin. FPy was found to induce apoptosis in 74 þ 8% of total
cells at 50 WM by itself on the basis of the appearance of cells
with fragmented nuclear particles (Fig. 5A). The ratio of apo-
ptotic cells was further increased with the coaddition of Act D
but their apoptotic bodies formation could be scarcely in-
duced under the condition with 50 WM FPy (Fig. 5B). FPy
signi¢cantly lost the ability to induce apoptosis at 12.5 WM by
itself whereas the analog was still e¡ective for preventing apo-
ptotic body formation of Act D-treated cells at this concen-
tration. FPy was more protective against apoptotic body for-
mation of HL-60 cells when apoptosis was induced by
anisomycin (Fig. 5C). These ¢ndings indicate that FPy can
exhibit such a protective e¡ect against apoptotic body forma-
tion independently of its apoptosis-inducing activity.
A fungal metabolite, jasplakinolide, is known to exhibit
profound e¡ects not only on the morphology of apoptotic
cells but also on apoptosis induction in HL-60 cells [19]. Pro-
nounced actin polymerization induced by the agent corre-
sponds morphologically with prominent membrane blebbing,
but with little apoptotic body formation. We therefore exam-
ined whether FPy can in£uence the actin polymerization sta-
tus as is the case with H2CB or jasplakinolide. As reported by
Levee et al. [16], actin ¢laments were visible as a haze-like
image brightly stained with the £uorescent probe in untreated
cells at 6 h of incubation although individual micro¢laments
were not clearly resolved. When cells were treated with 1 WM
Act D alone for 6 h, apoptotic bodies but not unfragmented
cells were observed with brightly stained intracellular compo-
nent, re£ecting disorganization of actin micro¢laments during
the stage of apoptosis induction and its reorganization along
with apoptotic body formation [16]. In accordance with that
Fig. 1. Structures of FOH, FPy and LPy.
Fig. 2. Phase-contrast (A^D) and £uorescent microscopic observations (AP^DP) of HL-60 cells incubated in medium alone (A,AP), medium with
50 WM FPy (B,BP), medium with 125 WM FOH (C,CP) and medium with 12.5 WM LPy (D,DP) for 6 h.
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fact, actin micro¢laments were invisible in Act D-treated cells
when they were protected against fragmentation into apopto-
tic bodies with the coaddition of 10 WM H2CB. Actin micro-
¢laments were invisible when apoptotic cells were prevented
from apoptotic body formation in medium with 50 WM FPy
alone as well as in medium with both 50 WM FPy and 1 WM
Act D. These ¢ndings suggested that FPy showed an H2CB-
like activity such as preventing repolymerization of actin mi-
cro¢laments that had been depolymerized due to its apopto-
sis-inducing activity.
In addition to the inhibition by cytochalasins, the formation
of apoptotic bodies was prevented in HL-60 cells by the ad-
dition of benzamide or 3-aminobenzamide, an inhibitor of
PARP [17], and in human myeloma RPMI 8226 cells by dex-
amethasone [18]. Dexamethasone was found to repress trans-
glutaminase during the retinoic acid-induced apoptosis. Un-
like the case with FPy and H2CB, these agents could suppress
nuclear condensation or fragmentation as well, although they
were permissive for DNA fragmentation. Our results reveal
that the structural modi¢cation of FOH generated an inhib-
itory activity against the mechanism essential for apoptotic
body formation independent of its activity of apoptosis induc-
tion. The molecular target of FPy is currently under investi-
gation with the aim of determining the reaction(s) most
closely involved in spatial arrangement of actin ¢lament.
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